Cargando…
Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
Integrase strand transfer inhibitor (INSTI)-containing regimens in HIV-1-infected patients have experienced a global increase. Recently, WHO has emphasized the need to fast-track the transition to dolutegravir (DTG)-based antiretroviral (ARV) treatments. However, continued surveillance of INSTI resi...
Autores principales: | Gil, Horacio, Delgado, Elena, Benito, Sonia, Moreno-Lorenzo, María, Thomson, Michael M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792149/ https://www.ncbi.nlm.nih.gov/pubmed/36578581 http://dx.doi.org/10.3389/fmicb.2022.1051096 |
Ejemplares similares
-
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014) -
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018) -
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
por: Santos, José Ramón, et al.
Publicado: (2023) -
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy
por: Huik, Kristi, et al.
Publicado: (2022) -
Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
por: Barski, Michał S., et al.
Publicado: (2019)